1887

Abstract

Human immunodeficiency virus 1 (HIV-1) diversity is a significant challenge in developing a vaccine against the virus. B/C recombinants have been found in India and other places but are the predominant clade prevalent in China. HIV-1 envelopes (Envs) are the target of broadly neutralizing antibodies (bNAbs) which develop spontaneously in some HIV-1 infected patients. It has been previously reported with efficiently cleaved clade A, B and C Envs that preferential binding of Envs to bNAbs as opposed to non-NAbs, a desirable property for immunogens, is correlated with efficient cleavage of the Env precursor polypeptide into constituent subunits. These Envs are suitable for designing immunogens as soluble proteins, virus-like particles or for delivery by viral vectors/plasmid DNA. However, a B/C recombinant Env with similar properties has not been reported. Here we show that the chimeric, recombinant B/C clade Env LT5.J4b12C is efficiently cleaved on the plasma membrane and selectively binds to bNAbs.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001141
2018-08-21
2019-10-21
Loading full text...

Full text loading...

/deliver/fulltext/jgv/99/10/1438.html?itemId=/content/journal/jgv/10.1099/jgv.0.001141&mimeType=html&fmt=ahah

References

  1. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009;5:e1000433 [CrossRef][PubMed]
    [Google Scholar]
  2. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010;84:1302–1313 [CrossRef][PubMed]
    [Google Scholar]
  3. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013;503:224–228 [CrossRef][PubMed]
    [Google Scholar]
  4. Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013;503:277–280 [CrossRef][PubMed]
    [Google Scholar]
  5. Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 2015;522:487–491 [CrossRef][PubMed]
    [Google Scholar]
  6. Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 2016;352:997–1001 [CrossRef][PubMed]
    [Google Scholar]
  7. Lu CL, Murakowski DK, Bournazos S, Schoofs T, Sarkar D et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 2016;352:1001–1004 [CrossRef][PubMed]
    [Google Scholar]
  8. Pancera M, Wyatt R. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 2005;332:145–156 [CrossRef][PubMed]
    [Google Scholar]
  9. Ringe RP, Sanders RW, Yasmeen A, Kim HJ, Lee JH et al. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci USA 2013;110:18256–18261 [CrossRef][PubMed]
    [Google Scholar]
  10. Boliar S, das S, Bansal M, Shukla BN, Patil S et al. An efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodies. PLoS One 2015;10:e0122443 [CrossRef][PubMed]
    [Google Scholar]
  11. das S, Boliar S, Mitra N, Samal S, Bansal M et al. Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes. Retrovirology 2016;13:81 [CrossRef][PubMed]
    [Google Scholar]
  12. das S, Boliar S, Samal S, Ahmed S, Shrivastava T et al. Identification and characterization of a naturally occurring, efficiently cleaved, membrane-bound, clade A HIV-1 Env, suitable for immunogen design, with properties comparable to membrane-bound BG505. Virology 2017;510:22–28 [CrossRef][PubMed]
    [Google Scholar]
  13. Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 2013;9:e1003618 [CrossRef][PubMed]
    [Google Scholar]
  14. Sharma SK, de Val N, Bale S, Guenaga J, Tran K et al. Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell Rep 2015;11:539–550 [CrossRef][PubMed]
    [Google Scholar]
  15. Guenaga J, de Val N, Tran K, Feng Y, Satchwell K et al. Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties. PLoS Pathog 2015;11:e1004570 [CrossRef][PubMed]
    [Google Scholar]
  16. Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 2015;349:aac4223 [CrossRef][PubMed]
    [Google Scholar]
  17. Feng Y, Tran K, Bale S, Kumar S, Guenaga J et al. Thermostability of well-ordered HIV spikes correlates with the elicitation of autologous tier 2 neutralizing antibodies. PLoS Pathog 2016;12:e1005767 [CrossRef][PubMed]
    [Google Scholar]
  18. Pauthner M, Havenar-Daughton C, Sok D, Nkolola JP, Bastidas R et al. Elicitation of robust tier 2 neutralizing antibody responses in nonhuman primates by hiv envelope trimer immunization using optimized approaches. Immunity 2017;46:1073–1088 [CrossRef][PubMed]
    [Google Scholar]
  19. Sok D, Le KM, Vadnais M, Saye-Francisco KL, Jardine JG et al. Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows. Nature 2017;548:108–111 [CrossRef][PubMed]
    [Google Scholar]
  20. Chakrabarti BK, Feng Y, Sharma SK, McKee K, Karlsson Hedestam GB et al. Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates. J Virol 2013;87:13239–13251 [CrossRef][PubMed]
    [Google Scholar]
  21. Law M, Maruyama T, Lewis J, Giang E, Tarr AW et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008;14:25–27 [CrossRef][PubMed]
    [Google Scholar]
  22. Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC et al. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 2008;82:7369–7378 [CrossRef][PubMed]
    [Google Scholar]
  23. Mukhopadhyay S, Ringe R, Patil A, Paranjape R, Bhattacharya J. Characterization of circulating HIV type 1 env genes in plasma of two antiretroviral-naive slow progressing patients with broad neutralizing antibody response with evidence of recombination. AIDS Res Hum Retroviruses 2012;28:739–745 [CrossRef][PubMed]
    [Google Scholar]
  24. Yang R, Xia X, Kusagawa S, Zhang C, Ben K et al. On-going generation of multiple forms of HIV-1 intersubtype recombinants in the Yunnan Province of China. AIDS 2002;16:1401–1407 [CrossRef][PubMed]
    [Google Scholar]
  25. Yu XF, Liu W, Chen J, Kong W, Liu B et al. Maintaining low HIV type 1 env genetic diversity among injection drug users infected with a B/C recombinant and CRF01_AE HIV type 1 in southern China. AIDS Res Hum Retroviruses 2002;18:167–170 [CrossRef][PubMed]
    [Google Scholar]
  26. Liu L, Wan Y, Xu J, Huang X, Wu L et al. Immunogenicity comparison between codon optimized HIV-1 CRF BC_07 gp140 and gp145 vaccines. AIDS Res Hum Retroviruses 2007;23:1396–1404 [CrossRef][PubMed]
    [Google Scholar]
  27. Ringe R, Das L, Choudhary I, Sharma D, Paranjape R et al. Unique C2V3 sequence in HIV-1 envelope obtained from broadly neutralizing plasma of a slow progressing patient conferred enhanced virus neutralization. PLoS One 2012;7:e46713 [CrossRef][PubMed]
    [Google Scholar]
  28. Kumar R, Ozorowski G, Kumar V, Holden LG, Shrivastava T et al. Characterization of a stable HIV-1 B/C recombinant, soluble, and trimeric envelope glycoprotein (Env) highly resistant to CD4-induced conformational changes. J Biol Chem 2017;292:15849–15858 [CrossRef][PubMed]
    [Google Scholar]
  29. Ringe R, Thakar M, Bhattacharya J. Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection. Retrovirology 2010;7:76 [CrossRef][PubMed]
    [Google Scholar]
  30. Cao L, Diedrich JK, Kulp DW, Pauthner M, He L et al. Global site-specific N-glycosylation analysis of HIV envelope glycoprotein. Nat Commun 2017;8:14954 [CrossRef][PubMed]
    [Google Scholar]
  31. Chen J, Kovacs JM, Peng H, Rits-Volloch S, Lu J et al. HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein. Science 2015;349:191–195 [CrossRef][PubMed]
    [Google Scholar]
  32. Kovacs JM, Noeldeke E, Ha HJ, Peng H, Rits-Volloch S et al. Stable, uncleaved HIV-1 envelope glycoprotein gp140 forms a tightly folded trimer with a native-like structure. Proc Natl Acad Sci USA 2014;111:18542–18547 [CrossRef][PubMed]
    [Google Scholar]
  33. Shrivastava T, Samal S, Tyagi AK, Goswami S, Kumar N et al. Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response. Vaccine 2018;36:1627–1636 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001141
Loading
/content/journal/jgv/10.1099/jgv.0.001141
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error